Evidence map›Paper›PMID 35484993›Full record

ArticleBioengineered2022

Downregulated miR-18a and miR-92a synergistically suppress non-small cell lung cancer via targeting

Xinju Zhang, Xianyi Wang, Binshu Chai, Zong Wu, Xiaomin Liu, Heng Zou, Ziyi Hua, Zhongliang Ma, Weiwei Wang

Open access · goldAbstract read
In one paragraph

Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Advances in applications of artificial intelligence algorithms for cancer-related miRNA research.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2024
    Review
  8. Role of SPRY4 in health and disease.Frontiers in oncology · 2024
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xinju ZhangLab for Noncoding RNA & Cancer, Shanghai University, Shanghai, China.
Xianyi WangLab for Noncoding RNA & Cancer, Shanghai University, Shanghai, China.
Binshu ChaiLab for Noncoding RNA & Cancer, Shanghai University, Shanghai, China.
Zong WuLab for Noncoding RNA & Cancer, Shanghai University, Shanghai, China.
Xiaomin LiuLab for Noncoding RNA & Cancer, Shanghai University, Shanghai, China.
Heng ZouLab for Noncoding RNA & Cancer, Shanghai University, Shanghai, China.
Ziyi HuaExperimental Center for Life Science, Shanghai University, Shanghai, China.
Zhongliang MaLab for Noncoding RNA & Cancer, Shanghai University, Shanghai, China.ORCID 0000-0002-4429-5213
Weiwei WangDepartment of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, China.
Shanghai University · CNKunming Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a novel noncoding RNA cluster, miR-17-92 cluster include six members: miR-17, miR-18a, miR-19a, miR-19b-1, miR-20a, and miR-92a. Dysregulation of miR-17-92 has been proved to be connected with the advancement of a series of human diseases, but the roles of miR-17-92 cluster in non-small cell lung cancer (NSCLC) have not been absolutely elaborated. Herein, we determined that miR-17-92 cluster were upregulated significantly in NSCLC tissues, and the cell proliferation, migration and cycle progression of NSCLC were also facilitated under the function of miR-17-92 cluster.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsMicroRNAsAnimalsCell Line, TumorCell ProliferationHumansMiceMicroRNAsMIRN18A microRNA, humanmiR-18amiR-92aNSCLCSPRY4

Identifiers

PMID35484993
PMCPMC9208480
OpenAlexW4225114823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.